Lv3
280 积分 2021-12-09 加入
Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
7个月前
已完结
Development and validation of an enzyme-linked immunosorbent assay for the quantification of a recombinant humanized anti-IL-4Rα monoclonal antibody CM310 in serum and its application to pharmacokinetic study in Sprague-Dawley Rats
1年前
已完结
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Stapokibart in Healthy Volunteers and Adult Subjects with Atopic Dermatitis
1年前
已完结
Efficacy and Safety of Extending Dosing Interval of Stapokibart in Patients with Atopic Dermatitis
1年前
已完结
410 Dupilumab treatment reduces total IgE levels in patients 6 months and older with moderate-to-severe atopic dermatitis
1年前
已关闭
Dupilumab reduces inflammatory biomarkers in pediatric patients with moderate-to-severe atopic dermatitis
1年前
已完结
Stapokibart Rapidly and Consistently Improves the Clinical Signs Across All Body Regions in Adults With Moderate‐to‐Severe Atopic Dermatitis
1年前
已完结
Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis Treated with Stapokibart over 52 weeks: A Post Hoc Analysis of a Phase 3 Trial
1年前
已完结
Long-Term Stapokibart Treatment Induces Sustained Clinical Improvements in Patients With Moderate-to-Severe Atopic Dermatitis
1年前
已完结
Efficacy and Safety of Extending Dosing Interval of Stapokibart in Patients with Atopic Dermatitis
1年前
已关闭
皖公网安备34019202002308
